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Purpose or Objective: The radiation therapy of head and 
neck tumors is burdened by high toxicity to organs at risk 
(OARs) with consequent administered dose limitations to the 
target and compromised clinical outcome. We investigated 
the contribution of functional/biological imaging obtained by 
Positron Emission Tomography (PET/CT) in Gross Tumor 
Volume (GTV) and Clinical Target Volume (CTV) definition of 
primary tumor and regional lymph nodes in head and neck 
cancer, for a more accurate target delimitation resulting in 
lower toxicity to OARs. 
 
Material and Methods: From March 2103 to June 2014 we 
examined 51 patients with head and neck cancer and defined 
clinical volumes with the aid of only morphological CT images 
and with the aid of diagnostic PET/CT images. Then we 
evaluated, through tests of statistical significance, the 
overlap of GTV and CTV obtained with each of the two 
methods respectively. Moreover usefulness of PET/CT in 
preventing geographic errors for a more accurate target 
definition, resulting in peritumoral tissues preservation and 
less toxicity to the OARs, was evaluated as well. The 
influence of two different imaging techniques in TNM staging, 
which is important for treatment planning, was investigated. 
 
Results: In 33 of 51 patients the TNM staging obtained by 
PET/CT was similar to that performed by CT images, but in 
39% of the cases the primary tumor GTV defined by PET/CT 
was significantly smaller and restricted compared to that 
defined by CT only (p <0.016). Due to the better GTV 
definition in terms of size and location, the OARs are 
potentially better preserved. In 12 patients the more 
accurate definition of tumor margins made possible by 
PET/CT produced a different T than that obtained with CT 
evaluation only; in 6 patients PET/CT identified metastases 
to regional lymph nodes not assessed with CT images only. It 
was not observed significant variation of the nodal volumes. 
 
Conclusion: The use of PET/CT imaging allows the realization 
of more precise target volume and better defined clinical 
volumes, with a possible better preservation of the OARs and 
lower toxicity. Functional imaging PET/CT helps the radiation 
oncologist not only in the process of treatment planning, but 
has the advantage of identify treatable disease not 
highlighted on morphological CT images. It is therefore 
recommended to use a PET/CT scan in the radiotherapy 
planning process in order to achieve a more appropriate 
treatment planning in head and neck tumors. 
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Purpose or Objective: Concomitant radiotherapy + 
cetuximab association has shown superiority to exclusive 
radiotherapy for locally advanced head and neck cancers 
(LAHNC). Data on this association are scarce for the elderly 
despite its rising incidence. Initial clinical trials that led to its 
approval have not included patients>70 years. The objective 
of this study was to assess efficacy and toxicity of 
concomitant radiotherapy and cetuximab for patients 
aged>70 years with LAHNC 
 
Material and Methods: A retrospective monocentric data 
collection was performed in the Antoine Lacassagne center, 
France. Inclusion criterias were: age>70 years at time of 
diagnosis, histologically proven LAHNC, treated with 
radiotherapy combined with cetuximab. Non-inclusion 
criterias were: previous radiotherapy and metastases at time 
of diagnosis 
 
Results: Thirty-five patients were included between 2008 and 
2012. Median follow up was 22 months. Median age was 74 
years (70-86). Median performance status was 1(0-2). 
Female/male sex ratio was 0.34. Tumor sites were: 
Oropharynx(57.1%), larynx(20%), hypopharynx(14.3%), oral 
cavity(2.9%), rhinopharynx(2.9%), lymph node with unknown 
primary(2.9%). Using TNM classification, tumors were: 
T1(5.9%), T2(35.3%), T3(35.3%), T4(22.9%), N0(28.6%), 
N1(8.6%), N2(48.6%), N3(14.3%). Median radiotherapy dose 
was 70 Gy(60-70). 40% of patients were treated with 
intensity-modulated radiotherapy, the rest were treated with 
conventional 3D radiotherapy. 94.3% of patients paused 
radiotherapy due to toxicity. 29% had a cetuximab dose-
reduction and 1 patient had a definitive interruption. Median 
survivals were respectively: 49 months for overall 
survival(Standard-Error (SE)=8) and 32 months for relapse 
free survival(SE=10). Two-year local-regional relapse and 
metastatic relapse free survivals were respectively 
59%(SE=10) and 74%(SE=10). Median body mass index (BMI) 
was 24.6(17.3–38) before treatment and 23, 24 after 
treatment(16.3–34.7). Median weight variation was 4 
kilograms(-16 to +6). Ninety-four percent of patients had 
nutritional support: 37.8% had oral nutritional supplements 
only, 56.8% had enteral nutrition and 2.7% parenteral 
nutrition. Skin reaction and mucositis were the major 
toxicities recorded. Toxicities details are reported in table 1 
 
 
Conclusion: Concomitant radiotherapy and cetuximab seems 
to be an effective therapy in the elderly population with 
encouraging results similar to the literature concerning its 
efficacy and toxicity. This treatment should be considered 
for patients > 70 years. 
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Purpose or Objective: In an era of personalized treatment 
there is a great interest in identifying factors which might 
help to predict patient response to RT. EGFR role in this 
